Jean-Pierre  Bizzari net worth and biography

Jean-Pierre Bizzari Biography and Net Worth

Dr. Bizzari brings extensive experience in oncology drug development. He was Executive Vice President and Global Head of Oncology at Celgene Corporation, responsible for Celgene’s clinical development and operations-statistics teams across the U.S., Europe and Asia/Japan where he oversaw the development and approval of a number of leading oncology products, including REVLIMID® (lenalidomide), VIDAZA®(azacitidine), ISTODAX® (romidepsin) and ABRAXANE® (nab-paclitaxel). In addition, he was Chairman of Celgene’s hematology oncology development committee and a member of the company’s management committee. Prior to Celgene, Dr. Bizzari was the Vice President, Clinical Oncology Development for Sanofi-Aventis where he oversaw the approval of Eloxatin® (oxaliplatin), Taxotere® (docetaxel) and Elitek® (rasburicase). Prior to that he was Vice President, Clinical Development Oncology for Sanofi-Synthelabo and had previously held the same role for Rhône-Poulenc Rorer. Dr. Bizzari is a member of the Scientific Advisory Board of France’s National Cancer Institute and a member of the board of directors of Compugen Ltd., Nordic Nanovector ASA, Onxeo SA, and Transgene SA. He is a Doctor of Medicine, a graduate of the Nice Medical School and a specialist in oncology (training in Toronto and Montreal). Dr. Bizzari was also an assistant in the medical oncology department at La Pitié-Salpêtrière hospital in Paris. Dr. Bizzari serves on the Nominating and Corporate Governance Committee.

How do I contact Jean-Pierre Bizzari?

The corporate mailing address for Mr. Bizzari and other Halozyme Therapeutics executives is 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA, 92121-1345. Halozyme Therapeutics can also be reached via phone at 858-794-8889 and via email at [email protected]. Learn More on Jean-Pierre Bizzari's contact information.

Has Jean-Pierre Bizzari been buying or selling shares of Halozyme Therapeutics?

Jean-Pierre Bizzari has not been actively trading shares of Halozyme Therapeutics over the course of the past ninety days. Most recently, Jean-Pierre Bizzari sold 35,000 shares of the business's stock in a transaction on Wednesday, August 25th. The shares were sold at an average price of $41.01, for a transaction totalling $1,435,350.00. Learn More on Jean-Pierre Bizzari's trading history.

Who are Halozyme Therapeutics' active insiders?

Halozyme Therapeutics' insider roster includes Jean-Pierre Bizzari (Director), James Daly (Director), Jeffrey Henderson (Director), Kenneth Kelley (Director), Michael LaBarre (SVP), Nicole Labrosse (CFO), Connie Matsui (Director), Matthew Posard (Director), and Helen Torley (CEO). Learn More on Halozyme Therapeutics' active insiders.

Are insiders buying or selling shares of Halozyme Therapeutics?

In the last year, insiders at the biopharmaceutical company sold shares 18 times. They sold a total of 180,000 shares worth more than $7,501,100.00. The most recent insider tranaction occured on June, 11th when Director Matthew L Posard sold 10,000 shares worth more than $500,100.00. Insiders at Halozyme Therapeutics own 2.7% of the company. Learn More about insider trades at Halozyme Therapeutics.

Information on this page was last updated on 6/11/2024.

Jean-Pierre Bizzari Insider Trading History at Halozyme Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/25/2021Sell35,000$41.01$1,435,350.00View SEC Filing Icon  
See Full Table

Jean-Pierre Bizzari Buying and Selling Activity at Halozyme Therapeutics

This chart shows Jean-Pierre Bizzari's buying and selling at Halozyme Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Halozyme Therapeutics Company Overview

Halozyme Therapeutics logo
Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $50.27
Low: $49.00
High: $50.84

50 Day Range

MA: $43.22
Low: $37.81
High: $51.44

2 Week Range

Now: $50.27
Low: $32.83
High: $53.00

Volume

1,035,343 shs

Average Volume

1,305,459 shs

Market Capitalization

$6.40 billion

P/E Ratio

20.77

Dividend Yield

N/A

Beta

1.28